| 0 |
DRUG INEFFECTIVE |
85 |
| 1 |
NO ADVERSE EVENT |
60 |
| 2 |
PAIN |
6 |
| 3 |
RASH |
6 |
| 4 |
THERAPEUTIC RESPONSE DECREASED |
6 |
| 5 |
APPLICATION SITE PAIN |
5 |
| 6 |
PRODUCT QUALITY ISSUE |
5 |
| 7 |
SKIN BURNING SENSATION |
5 |
| 8 |
BLISTER |
4 |
| 9 |
PAIN IN EXTREMITY |
4 |
| 10 |
APPLICATION SITE BURN |
3 |
| 11 |
CONDITION AGGRAVATED |
3 |
| 12 |
DIZZINESS |
3 |
| 13 |
DRUG HYPERSENSITIVITY |
3 |
| 14 |
FALL |
3 |
| 15 |
FATIGUE |
3 |
| 16 |
FEELING ABNORMAL |
3 |
| 17 |
POST-ACUTE COVID-19 SYNDROME |
3 |
| 18 |
PRODUCT DOSE OMISSION ISSUE |
3 |
| 19 |
PRODUCT USE ISSUE |
3 |
| 20 |
PRURITUS |
3 |
| 21 |
ANXIETY |
2 |
| 22 |
APPLICATION SITE RASH |
2 |
| 23 |
ATRIAL FIBRILLATION |
2 |
| 24 |
BLINDNESS |
2 |
| 25 |
BURNS THIRD DEGREE |
2 |
| 26 |
COUGH |
2 |
| 27 |
DISCOMFORT |
2 |
| 28 |
DRUG EFFECT LESS THAN EXPECTED |
2 |
| 29 |
ENERGY INCREASED |
2 |
| 30 |
INSOMNIA |
2 |
| 31 |
MALAISE |
2 |
| 32 |
MUSCULOSKELETAL STIFFNESS |
2 |
| 33 |
NEURALGIA |
2 |
| 34 |
NEUROPATHY PERIPHERAL |
2 |
| 35 |
OFF LABEL USE |
2 |
| 36 |
PRODUCT ADHESION ISSUE |
2 |
| 37 |
PRODUCT PHYSICAL CONSISTENCY ISSUE |
2 |
| 38 |
RASH ERYTHEMATOUS |
2 |
| 39 |
SCAR |
2 |
| 40 |
TACHYCARDIA |
2 |
| 41 |
URTICARIA |
2 |
| 42 |
WEIGHT INCREASED |
2 |
| 43 |
ABDOMINAL DISCOMFORT |
1 |
| 44 |
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED |
1 |
| 45 |
ADMINISTRATION SITE NERVE DAMAGE |
1 |
| 46 |
ANAPHYLACTIC REACTION |
1 |
| 47 |
APPLICATION SITE IRRITATION |
1 |
| 48 |
APPLICATION SITE VESICLES |
1 |
| 49 |
ARTHRALGIA |
1 |
| 50 |
ARTHRITIS |
1 |
| 51 |
ARTHROPATHY |
1 |
| 52 |
BACK PAIN |
1 |
| 53 |
BLOOD CREATININE DECREASED |
1 |
| 54 |
BLOOD GLUCOSE INCREASED |
1 |
| 55 |
BLOOD PRESSURE DECREASED |
1 |
| 56 |
BLOOD PRESSURE DIASTOLIC INCREASED |
1 |
| 57 |
BLOOD PRESSURE SYSTOLIC INCREASED |
1 |
| 58 |
BLOOD URINE PRESENT |
1 |
| 59 |
BODY MASS INDEX INCREASED |
1 |
| 60 |
BODY TEMPERATURE DECREASED |
1 |
| 61 |
BRONCHITIS |
1 |
| 62 |
BURN INFECTION |
1 |
| 63 |
BURNING SENSATION |
1 |
| 64 |
BURNS SECOND DEGREE |
1 |
| 65 |
CANDIDA INFECTION |
1 |
| 66 |
CARBON DIOXIDE INCREASED |
1 |
| 67 |
CATARACT OPERATION |
1 |
| 68 |
CELLULITIS |
1 |
| 69 |
CHEMICAL BURN |
1 |
| 70 |
CHEMICAL INJURY |
1 |
| 71 |
CHEST DISCOMFORT |
1 |
| 72 |
CHONDROCALCINOSIS |
1 |
| 73 |
COAGULATION TIME PROLONGED |
1 |
| 74 |
COMPRESSION FRACTURE |
1 |
| 75 |
CONSTIPATION |
1 |
| 76 |
COVID-19 |
1 |
| 77 |
DEATH |
1 |
| 78 |
DECREASED APPETITE |
1 |
| 79 |
DEPRESSED MOOD |
1 |
| 80 |
DERMATITIS |
1 |
| 81 |
DIABETIC NEPHROPATHY |
1 |
| 82 |
DIABETIC RETINOPATHY |
1 |
| 83 |
DIARRHOEA |
1 |
| 84 |
DRY EYE |
1 |
| 85 |
DYSPNOEA |
1 |
| 86 |
ECZEMA |
1 |
| 87 |
ERYTHEMA |
1 |
| 88 |
ESSENTIAL HYPERTENSION |
1 |
| 89 |
EXPIRED PRODUCT ADMINISTERED |
1 |
| 90 |
EYE DISORDER |
1 |
| 91 |
EYE IRRITATION |
1 |
| 92 |
FIBROMYALGIA |
1 |
| 93 |
FURUNCLE |
1 |
| 94 |
GAIT DISTURBANCE |
1 |
| 95 |
GASTROOESOPHAGEAL REFLUX DISEASE |
1 |
| 96 |
GRANULOCYTE COUNT DECREASED |
1 |
| 97 |
HAEMATOCRIT DECREASED |
1 |
| 98 |
HAEMORRHAGE |
1 |
| 99 |
HEADACHE |
1 |
| 100 |
HEART RATE DECREASED |
1 |
| 101 |
HEPATIC CYST |
1 |
| 102 |
HERPES ZOSTER |
1 |
| 103 |
HOSPITALISATION |
1 |
| 104 |
HOT FLUSH |
1 |
| 105 |
HYPERCHLORAEMIA |
1 |
| 106 |
HYPERHIDROSIS |
1 |
| 107 |
HYPERNATRAEMIA |
1 |
| 108 |
HYPERPHAGIA |
1 |
| 109 |
HYPERTENSION |
1 |
| 110 |
HYPOACUSIS |
1 |
| 111 |
HYPOAESTHESIA |
1 |
| 112 |
HYPOKINESIA |
1 |
| 113 |
HYPONATRAEMIA |
1 |
| 114 |
IMMATURE GRANULOCYTE PERCENTAGE INCREASED |
1 |
| 115 |
INAPPROPRIATE RELEASE OF PRODUCT FOR DISTRIBUTION |
1 |
| 116 |
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION |
1 |
| 117 |
INFLAMMATION |
1 |
| 118 |
INTENTIONAL PRODUCT MISUSE |
1 |
| 119 |
INTRAOCULAR PRESSURE INCREASED |
1 |
| 120 |
LEUKOPENIA |
1 |
| 121 |
LIGAMENT SPRAIN |
1 |
| 122 |
LIMB DISCOMFORT |
1 |
| 123 |
LIMB INJURY |
1 |
| 124 |
LIVER DISORDER |
1 |
| 125 |
LOSS OF CONSCIOUSNESS |
1 |
| 126 |
LOW DENSITY LIPOPROTEIN INCREASED |
1 |
| 127 |
LYMPHOCYTE COUNT INCREASED |
1 |
| 128 |
LYMPHOEDEMA |
1 |
| 129 |
MACULAR DEGENERATION |
1 |
| 130 |
MEAN CELL HAEMOGLOBIN CONCENTRATION DECREASED |
1 |
| 131 |
MEMORY IMPAIRMENT |
1 |
| 132 |
MICROALBUMINURIA |
1 |
| 133 |
MOBILITY DECREASED |
1 |
| 134 |
MONOCYTE COUNT INCREASED |
1 |
| 135 |
MULTIPLE ALLERGIES |
1 |
| 136 |
MUSCLE HYPERTROPHY |
1 |
| 137 |
MUSCLE NECROSIS |
1 |
| 138 |
MUSCLE STRAIN |
1 |
| 139 |
NEPHROLITHIASIS |
1 |
| 140 |
NERVE INJURY |
1 |
| 141 |
NEUTROPHIL COUNT DECREASED |
1 |
| 142 |
NICOTINE DEPENDENCE |
1 |
| 143 |
NOCTURIA |
1 |
| 144 |
OESOPHAGEAL NEOPLASM |
1 |
| 145 |
OSTEOARTHRITIS |
1 |
| 146 |
OSTEOPENIA |
1 |
| 147 |
OSTEOPOROSIS |
1 |
| 148 |
OXYGEN SATURATION DECREASED |
1 |
| 149 |
PALPITATIONS |
1 |
| 150 |
PARAESTHESIA |
1 |
| 151 |
PELVIC PAIN |
1 |
| 152 |
PERIPHERAL COLDNESS |
1 |
| 153 |
PERIPHERAL SWELLING |
1 |
| 154 |
PERIPHERAL VASCULAR DISORDER |
1 |
| 155 |
PERIPHERAL VENOUS DISEASE |
1 |
| 156 |
PNEUMONIA |
1 |
| 157 |
PRODUCT ADMINISTRATION ERROR |
1 |
| 158 |
PRODUCT DISPENSING ERROR |
1 |
| 159 |
PRODUCT FORMULATION ISSUE |
1 |
| 160 |
PRODUCT PACKAGING DIFFICULT TO OPEN |
1 |
| 161 |
PRODUCT STORAGE ERROR |
1 |
| 162 |
PRODUCT USE IN UNAPPROVED INDICATION |
1 |
| 163 |
PROTEIN TOTAL DECREASED |
1 |
| 164 |
PSORIATIC ARTHROPATHY |
1 |
| 165 |
RASH PAPULAR |
1 |
| 166 |
RASH PRURITIC |
1 |
| 167 |
RED CELL DISTRIBUTION WIDTH INCREASED |
1 |
| 168 |
RESPIRATORY DISORDER |
1 |
| 169 |
SECOND DEGREE CHEMICAL BURN OF SKIN |
1 |
| 170 |
SEIZURE |
1 |
| 171 |
SEPSIS |
1 |
| 172 |
SKIN EXFOLIATION |
1 |
| 173 |
SKIN INJURY |
1 |
| 174 |
SKIN LESION |
1 |
| 175 |
SKIN ULCER |
1 |
| 176 |
SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION |
1 |
| 177 |
SOMNOLENCE |
1 |
| 178 |
STASIS DERMATITIS |
1 |
| 179 |
STENOSIS |
1 |
| 180 |
SYSTEMIC LUPUS ERYTHEMATOSUS |
1 |
| 181 |
THERAPEUTIC PRODUCT EFFECT DECREASED |
1 |
| 182 |
THERAPEUTIC RESPONSE SHORTENED |
1 |
| 183 |
THERAPY INTERRUPTED |
1 |
| 184 |
TRANSFERRIN SATURATION DECREASED |
1 |
| 185 |
TYPE 2 DIABETES MELLITUS |
1 |
| 186 |
TYPE V HYPERLIPIDAEMIA |
1 |
| 187 |
URINARY TRACT INFECTION |
1 |
| 188 |
VENOUS HYPERTENSION |
1 |
| 189 |
VISUAL IMPAIRMENT |
1 |
| 190 |
VITAMIN B12 INCREASED |
1 |
| 191 |
WALKING AID USER |
1 |
| 192 |
WHEEZING |
1 |
| 193 |
WHITE BLOOD CELL COUNT DECREASED |
1 |
| 194 |
WOUND INFECTION |
1 |
| 195 |
WOUND NECROSIS |
1 |
| 196 |
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS |
1 |